Tekla World Healthcare Fund: insider trades · United States · SEC (Form 4)

About Tekla World Healthcare Fund

Tekla World Healthcare Fund (NYSE: THW) is a U.S.-listed closed-end fund organized as a Massachusetts business trust and registered with the SEC as a non-diversified investment company. Its stated objective is to seek current income and long-term capital appreciation. The fund was formed on March 5, 2015, and it has been marketed as a listed vehicle designed to give investors broad, exchange-traded access to the global healthcare complex rather than a single-subindustry bet. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1635977/000110465922068028/tm228078d1_ncsrs.htm?utm_source=openai)) From an investment standpoint, THW focuses primarily on healthcare companies in the United States and outside the United States, investing across both equity and debt securities. Its disclosures describe a flexible growth-and-income approach spanning the main healthcare subsectors, including pharmaceuticals, biotechnology, healthcare technology, life sciences tools, medical devices, healthcare services, and related equipment and facilities. The fund may also use convertible securities and, selectively, covered-call writing to help generate income. In practical terms, THW is built for investors who want a diversified, thematic healthcare allocation with an income overlay. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001635977/000110465922126998/tm2226039d6_424b5.htm?utm_source=openai)) In terms of competitive positioning, Tekla World Healthcare Fund sits in a specialist niche. It is not a broad market ETF and not a pure biotech fund; instead, it offers a more diversified healthcare mandate with a meaningful global bias. That distinction matters for investors seeking exposure to long-duration healthcare trends such as aging populations, innovation in therapies, advances in medical technology, and the globalization of healthcare research and commercialization. The fund’s policy of maintaining substantial non-U.S. exposure also sets it apart from many U.S.-centric healthcare products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1635977/000110465921146323/tm2129557d1_ncsr.htm?utm_source=openai)) Historically, THW was associated with Tekla Capital Management LLC, a Boston-based healthcare specialist, but there was a material change in October 2023 when abrdn Inc. assumed responsibility for the management of four former Tekla closed-end funds, including THW. That transition is important for investors following governance, branding, and portfolio-management continuity. As of the latest SEC disclosures found, the fund remains listed on the NYSE in the United States and continues to operate within the healthcare sector with a global opportunity set. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884121/000110465924126672/tm2430035d6_ncsr.htm?utm_source=openai))